secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jasper Therapeutics, Inc. (JSPR)
CIK:        0001788028
Form:       8-K
Filed at:   2023-06-08T23:59:59+00:00
Accession:  0001213900-23-047446
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jasper Therapeutics increases inducement equity plan to 5.5M shares; charter amended for officer exculpation
--------------------------------------------------------------------------------

- Compensation Committee approved amendment to 2022 Inducement Plan, increasing shares from 3M to 5.5M (2.5M new shares).
- Amendment adopted without stockholder approval under Nasdaq Rule 5635(c)(4) for inducement awards to new employees.
- At June 7 Annual Meeting, stockholders elected Anna French and Judith Shizuru as Class II directors.
- Stockholders ratified PricewaterhouseCoopers as independent auditor for FY2023.
- Stockholders approved amendment to Certificate of Incorporation for officer exculpation under new Delaware law.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1788028/000121390023047446/0001213900-23-047446-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1788028/000121390023047446/ea179979-8k_jasper.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-047446

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer